Phosphoinositide 3-Kinase Function in Lymphocytes
Phosphoinositide 3-Kinase Function in Lymphocytes
批准号:
6609015
负责人:
DAVID Alexander FRUMAN
金额:
$2.23万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-15 至 2006-06-30
中文摘要
描述(申请者提供):本项目的远景目标是
明确磷脂酰肌醇3-激酶(PI3K)信号转导机制
淋巴细胞。由于PI3K是淋巴细胞增殖所必需的,因此在这方面的进展
区域可能导致治疗免疫缺陷的新策略,
自身免疫、移植排斥和癌症。指导核心假说
这个应用是PI3K调节亚型p85α和p85β具有
淋巴细胞信号转导中不同的功能作用。为了检验这一假设,
这位研究员S的实验室已经产生了缺乏p85α或p85的小鼠
P85β。P85α缺陷小鼠表现出与所见类似的B细胞缺陷
在缺乏BTK、BLNK或PLCGamma2的小鼠中。这些发现支持一个模型,该模型
PI3K激活对于信号复合体的膜组装是重要的
促进PLCGamma2的激活和持续的钙离子流动。T细胞和B细胞
细胞依赖不同的蛋白质来执行许多信号步骤,这些步骤
将抗原受体与钙离子流量和细胞增殖联系起来。例如,
T细胞内的钙离子流量受ITK调节,ITK是BTK的功能同源物。
初步结果提示p85β可能是一种重要的PI3K调节因子
T细胞信号转导中的异构体。这个应用程序有三个具体目标:目标1是
要测试激活BTK和PLCGamma2需要p85pha的模型
导致持续的钙离子流动。生化分析将被用来分析
缺乏p85α的原代B细胞和永生化B细胞系中的信号转导。
目的2是确定T细胞增殖和细胞因子是否需要p85β
制作。目标3是确定是否需要p85β来激活
ITK、PLCGamma1和T细胞持续的钙离子通量。生化分析将是
用于分析纯化的T细胞中的信号。这些研究将增加我们的
对淋巴细胞中枢控制点PI3K信号的认识
扩散。
英文摘要
DESCRIPTION (provided by applicant): The long-range goal of this project is to
define the mechanism of phosphoinositide 3-kinase (PI3K) signaling in
lymphocytes. As PI3K is required for lymphocyte proliferation, advances in this
area may lead to novel strategies for the treatment of immunodeficiency,
autoimmunity, transplant rejection and cancer. The central hypothesis guiding
this application is that the PI3K regulatory isoforms p85alpha and p85beta have
distinct functional roles in lymphocyte signaling. To test this hypothesis,
this investigator?s laboratory has generated mice lacking either p85alpha or
p85beta. p85alpha-deficient mice exhibit B cell defects similar to those seen
in mice lacking Btk, BLNK or PLCgamma2. These findings support a model that
PI3K activation is important for membrane assembly of a signaling complex that
facilitates PLCgamma2 activation and sustained calcium flux. T cells and B
cells rely on distinct proteins to carry out many of the signaling steps that
link the antigen receptor to calcium flux and proliferation. For example,
calcium flux in T cells is regulated by Itk, a functional homolog of Btk.
Preliminary results suggest that p85beta may be an important PI3K regulatory
isoform in T cell signaling. This application has three specific aims: Aim 1 is
to test the model that p85alpha is required for activation of Btk and PLCgamma2
leading to sustained Ca2+ flux. Biochemical assays will be used to analyze
signaling in primary B cells and immortalized B cell lines lacking p85alpha.
Aim 2 is determine if p85beta is required for T cell proliferation and cytokine
production. Aim 3 is to determine whether p85beta is required for activation of
Itk, PLCgamma1, and sustained Ca2+ flux in T cells. Biochemical assays will be
used to analyze signaling in purified T cells. These studies will increase our
understanding of PI3K signaling, a central control point in lymphocyte
proliferation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
-
批准号:9178942
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
-
批准号:9316613
-
项目类别:
-
资助金额:$19.77万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Regulation of B cell differentiation by eIF4E
-
批准号:9244731
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Combination strategies to enhance therapy for Ph-like B-ALL
-
批准号:8912208
-
项目类别:
-
资助金额:$25.67万
-
财政年份:2015
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:9341983
-
项目类别:
-
资助金额:$31.79万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:8929336
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:8829529
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Solving the elusive mechanism of rapamycin action in lymphocytes
-
批准号:8285697
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8628792
-
项目类别:
-
资助金额:$30.18万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Solving the elusive mechanism of rapamycin action in lymphocytes
-
批准号:8531852
-
项目类别:
-
资助金额:$21.72万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8815271
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8238745
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8442848
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Immunoregulatory effects of novel mTOR inhibitors
-
批准号:7774553
-
项目类别:
-
资助金额:$7.2万
-
财政年份:2010
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Immunoregulatory effects of novel mTOR inhibitors
-
批准号:8019056
-
项目类别:
-
资助金额:$7.12万
-
财政年份:2010
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
LIVE CELL IMAGING OF CD4+ T-CELL CHEMOKINESIS OVER IMMOBILIZED CCL21
-
批准号:7724055
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2008
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
PI3K Signaling in Single Lymphocytes Analyzed by LMS
-
批准号:6710897
-
项目类别:
-
资助金额:$18.54万
-
财政年份:2004
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
PI3K Signaling in Single Lymphocytes Analyzed by LMS
-
批准号:6878064
-
项目类别:
-
资助金额:$22.4万
-
财政年份:2004
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Phosphoinositide 3-Kinase Function in Lymphocytes
-
批准号:6837137
-
项目类别:
-
资助金额:$34.29万
-
财政年份:2002
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Phosphoinositide 3-Kinase Function in Lymphocytes
-
批准号:6620748
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2002
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
海外基金